Authors
Latest:
Addressing the Knowledge Gap in Biologics & Biosimilars: Is a Board Certified Biologics and Biosimilars Program the Answer?Life sciences professionals will need to keep up with market demand for biologics and biosimilars.
Latest:
Strategic Market Access Ensures the Right Treatments at the Right TimeA robust market access strategy ensures that pharmaceutical products, including those with limited distribution, reach patients and are covered by diverse healthcare systems.
Latest:
Rethinking Market Strategy within a Patient-Centric EraA panel of industry leaders share key insights supporting the integration of patient-centric strategies into current and future drug development and market access efforts.
Latest:
Forging a Brighter Future for Rare Disease Outcomes with Specialty Pharmacy UtilizationThese diseases require specialty treatment typically unavailable at local retail pharmacies or small health systems, making it extremely difficult for many patients to get the care they need.
Latest:
Breaking OrbitHow pharmaceutical leaders at established companies can still disrupt the status quo and change the game.
Latest:
Going Beyond Compliance: Early Adoption of FDA’s Quality Management Maturity Program—and the Practical Considerations for ExecutivesAn examination of proactive preparedness and readiness review for future enrollment in the agency’s QMM program—now in the pilot stage as an effort to incentivize pharma manufacturers to achieve a more mature state of quality culture.
Latest:
The Impact of Accelerated Drug DevelopmentDr. Manuel Hermosilla shares his thoughts on how the pharmaceutical industry reacts to challenges that arise during trials, specifically during the search for an effective COVID-19 vaccine.
Latest:
What the Leaders of the Most Effective Teams KnowFindings from hundreds of interviews of exceptional pharma leaders around the world.
Latest:
Ask a Better Question, Make a Better Decision.Harnessing the power of curiosity to position your next big idea
Latest:
Navigating the Payer-Health System Nexus: A Strategic Imperative for Biopharma Commercial SuccessThe traditional biopharma approach focused primarily on physician detailing and securing favorable payer contracts, has become inadequate in today’s market.
Latest:
Point of Care Lifts Reps EffortsPoint of Care and PatientPoint can improve the impact that your Pharma Reps are already having.
Latest:
Rethinking Market Access in CEE: Time to Bust the MythsChallenging six misconceptions that have characterized product strategies in Central and Eastern European markets.
Latest:
China 2021 National Reimbursement Drug List OutlookThe 2021 National Reimbursement Drug List (NRDL) process has been unfolding in China since June this year, with several key themes emerging. Building on Simon-Kucher’s experience with the NRDL, the authors make three recommendations on negotiation strategies going into the process.
Latest:
Clues on Equity Engagement LevelsA survey of 18 biopharmas, measuring their scope and implementation across key health equity dimensions and activities, uncovers useful context as companies seek better alignment of these goals with overall strategy.
Latest:
Oncology Brands Face Uniquely Complex Market Access Challenges: A Specialized Approach for Commercial SuccessThe high-stakes nature of cancer care, coupled with rapid scientific advancements and increasing payer and regulatory pressures, demands a specialized approach beyond traditional market access strategies.
Latest:
Payers Believe Lowering Drug Prices While Improving Patient Access Is Possible—but There’s a CatchValue-based price for access (VBPA) may increase access of specialty drugs for patients.
Latest:
The Rebound Effect: What Happens After GLP-1?Researchers are still studying the impact of going off a GLP-1 medication.
Latest:
Navigating Uncertainty with AI: Building Trust in the Way ForwardDespite surging GenAI adoption in pharma and the FDA’s recent embrace of the technology, a trust gap remains with GenAI implementations. The story describes four essentials that improve trust in GenAI so that pharma and biotech teams can better navigate the present time of uncertainty.
Latest:
Manage Risk Effectively to Improve the Value of Your AllianceIn this article, Eli Lilly & Co. examines risk management in the context of partnerships with other companies.
Latest:
The Benefits of Enhancing Adverse Event Intake With Case Collection SystemsAutomated risk management and improved regulatory compliance among opportunities offered by case collection.
Latest:
Anchoring HEOR Evidence Generation in the Challenge from the MarketHEOR scientists in the pharma industry must balance methodologic rigor with commercial expectations and timelines.
Latest:
COVID and AMR: Crisis Reframes Antibiotics FightThe redirection of healthcare and life sciences resources to COVID-19 has taken focus from other areas of need, including antimicrobial resistance.
Latest:
Solving One of the Hardest Questions in Cancer: How Do We Ensure Patient Access to Medicines?Pharmaceutical companies are facing new guidelines, laws, and regulations requiring a reconsideration of how to prioritize, develop, commercialize, and ultimately, secure access to medicines.
Latest:
Learning and Development Is the Key to Compliance in Life SciencesEmployees must be able to retain information and remain engaged to keep pace with highly regulated industry.
